AKTX · Akari Therapeutics Plc · Documents
$8.24
+0.24 (+3.00%)
At close · Oct 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our recurring losses from operations incurred since inception, our expectation of continuing operating losses for the foreseeable future, negative operating cash flows for the foreseeable future, and the need to raise additional capital to finance its future operations, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date that our condensed consolidated financial statements, included in this Form 10-Q (such condensed consolidated financial statements, the "consolidated financial statements") are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$18.83M
Shares
2.29M
Volume · Oct 30
45.8K
Avg daily vol (3M)
62.13K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | At its October 28, 2026 Special General Meeting, Akari Therapeutics, Plc shareholders approved increasing shares available for awards by 144,000,000,000 ordinary shares, from 19,806,000,000 to an aggregate 163,806,000,000. | 2026-10-30 | 2026-10-28 | |
| DEF 14A | Akari Therapeutics seeks approval to increase shares available under its 2023 Equity Incentive Plan by 144,000,000,000 to 163,806,000,000, including up to 855,637,300 shares from forfeited or cancelled Celsus Therapeutics PLC 2014 Equity Incentive Plan awards. | 2026-10-01 | — | |
| 8-K | Akari Therapeutics, Plc amended Abizer Gaslightwala’s CEO agreement, raising annual base salary from $475,000 to $625,000 effective August 18, 2026, target bonus from 50% to 55%, and granting options for 174,000 ADSs. | 2026-10-01 | 2026-09-29 | |
| 10-Q | — | 2026-08-13 | 2026-06-30 | |
| 8-K | — | 2026-08-13 | — | |
| S-3/A | — | 2026-07-10 | — | |
| S-3/A | — | 2026-07-08 | — | |
| S-3 | — | 2026-07-02 | — | |
| 8-K | — | 2026-07-02 | 2026-06-30 | |
| S-1/A | — | 2026-06-26 | — | |
| 8-K | — | 2026-06-26 | 2026-06-23 | |
| DEF 14A | — | 2026-06-04 | — | |
| 8-K | — | 2026-05-22 | 2026-05-20 | |
| PRE 14A | — | 2026-05-22 | — | |
| 10-Q | — | 2026-05-19 | 2026-03-31 | |
| NT 10-Q | — | 2026-05-18 | 2026-03-31 | |
| S-1 | — | 2026-05-08 | — | |
| 10-K | — | 2026-03-30 | 2025-12-31 | |
| 8-K | — | 2026-03-17 | — | |
| 8-K | — | 2026-03-02 | — | |
| DEF 14A | — | 2026-02-02 | — | |
| S-1 | — | 2026-01-23 | — | |
| PRE 14A | — | 2026-01-22 | — | |
| 8-K | — | 2025-12-17 | 2025-12-16 | |
| 8-K | — | 2025-12-16 | 2025-12-15 | |
| 8-K | — | 2025-12-08 | — | |
| 8-K | — | 2025-11-26 | 2025-11-24 | |
| DEF 14A | — | 2025-11-17 | — | |
| S-1 | — | 2025-11-17 | — | |
| 10-Q | — | 2025-11-13 | 2025-09-30 | |
| PRE 14A | — | 2025-11-07 | — | |
| 8-K | — | 2025-10-23 | 2025-10-22 | |
| 8-K | — | 2025-10-16 | 2025-10-14 | |
| 8-K | — | 2025-10-15 | — | |
| 8-K | — | 2025-09-29 | 2025-09-26 | |
| 8-K | — | 2025-09-25 | 2025-09-19 | |
| 8-K | — | 2025-08-29 | 2025-08-28 | |
| S-1 | — | 2025-08-29 | — | |
| 8-K | — | 2025-08-21 | 2025-08-15 | |
| 8-K | — | 2025-08-19 | — | |
| 10-Q | — | 2025-08-13 | 2025-06-30 | |
| S-3 | — | 2025-07-29 | — | |
| 8-K | — | 2025-07-01 | 2025-06-30 | |
| ARS | — | 2025-06-06 | 2024-12-31 | |
| DEF 14A | — | 2025-06-06 | — | |
| PRE 14A | — | 2025-05-23 | — | |
| 8-K | — | 2025-05-15 | — | |
| 10-Q | — | 2025-05-14 | 2025-03-31 | |
| S-3 | — | 2025-05-06 | — | |
| 8-K | — | 2025-04-16 | — |
Showing 1–50 of 192 filings